Abstract:FGF23 is a bone-derived hormone that regulates systemic phosphate homeostasis, vitamin D metabolism and α-Klotho expression through a novel bone-kidney axis. FGF23 inhibits renal tubular reabsorption of phosphate through mechanisms independent of PTH as well as reduces circulating 1, 25(OH)(2)D through its dual effects to suppress Cyp27b1 production and to stimulate Cyp24 catabolism of 1,25(OH)(2)D. 1,25(OH)(2)D and other factors regulating bone remodeling/mineralization are the major physiological regulators of FGF23 expression. FGF23 also suppresses the gene transcription of α-klotho by the kidney, which exists as a membrane and soluble protein. Membrane Klotho acts as a coreceptor for and dictates organ specificity of FGF23, whereas soluble Klotho act as an endocrine factor that regulates activity of cell surface glycoproteins and receptors in multiple tissues. Elevated FGF23 levels are responsible for several hereditary and acquired hypophosphatemic rickets disorders. FGF23 and Klotho deficiency have similar phenotypes characterized by hyperphosphatemia, elevated 1,25(OH)(2)D and tumoral calcinosis. FGF23 levels progressively increase during chronic kidney disease (CKD). FGF23 has been proposed to be the initial adaptive response leading to reductions in 1,25(OH)(2)D and secondary hyperparathyroidism (HPT) in CKD. The overall biological effect of this initial step may be to orchestrate a coordinated adaptation to protect the organism from the adverse effects of excess phosphate retention. The second step involves the effects of PTH on bone remodeling that further stimulates FGF23 production through both direct and indirect mechanisms related to alterations in extracellular matrix factors. PTH further amplifies FGF23 expression in later stages of CKD to compensate for the increased phosphate efflux from bone caused by excessive bone turnover. While many aspects of the regulation and functions of FGF23 remain to be established, the idea that FGF23 hormone is the initial adaptive hormonal response in CKD that suppresses 1,25(OH)(2)D, reduces gastrointestinal calcium and phosphate absorption and leads to a secondary HPT represents a paradigm shift in the conceptualization of the pathogenesis of secondary hyperparathyroidism. In addition, the prevalent thought that CKD is a functional "vitamin D deficient state" requiring therapy with 1,25(OH)(2)D analogs is challenged by effects of FGF23 to potentially lower both 25(OH)D and 1,25(OH)D by induction of Cyp24-mediated degradation. Finally, increments in FGF23 are associated with increased cardiovascular mortality in CKD. Whether these effects represent direct effects of FGF23 or represent a marker of other abnormalities in CKD remains to be determined.

FGF23 Synthesis and Activity

Regulation of FGF23 production and phosphate metabolism by bone–kidney interactions

Regulation of FGF23: Beyond Bone

FGF-23: More than a regulator of renal phosphate handling?

Phosphate Homeostasis, Inflammation and the Regulation of FGF-23

Regulation and Function of the FGF23/Klotho Endocrine Pathways

FGF23 signalling and physiology

Emerging concepts on the FGF23 regulation and activity

FGF23 and Vitamin D Metabolism

Non-Classical Effects of FGF23: Molecular and Clinical Features

FGF23 Actions on Target Tissues—With and Without Klotho

Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney disease

FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease

FGF23, Hypophosphatemia, and Emerging Treatments

FGF23 and disorders of phosphate homeostasis

New Therapies for Hypophosphatemia-Related to FGF23 Excess

Upstream Regulators of Fibroblast Growth Factor 23

Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization

Interactions between FGF23 and vitamin D

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism

Fibroblast Growth Factor 23/Klotho Axis in Chronic Kidney Disease